AsclepiX Therapeutics is focused on transforming the treatment of ocular diseases and cancer through the rapid clinical development of groundbreaking therapies aimed at empowering patients and their families around the world with the freedom to live their best lives.

Using pioneering computational biology methods, we have identified multiple families of peptides that are potent regulators of vascular homeostasis. Our clinical candidates are derived from these peptides and work through naturally existing, highly evolved, and self-regulating mechanisms of homeostasis that maintain our health and well-being.

Asclepix Logo

What We Do

Our lead candidate, AXT107, is a synthetic 20-mer peptide, derived from non-collagenous sequences of the collagen IV protein.  As described in our seminal publications in Science Translational Medicine and JCI Insight, AXT107 inhibits pro-angiogenic vascular endothelial growth factor receptor 2 (VEGFR2) and activates the vessel stabilizing receptor tyrosine kinase (Tie2), the two validated pathways for the treatment of retinal vascular diseases. Both mechanisms of actions are mediated by AXT107’s interaction with and disruption of the VEGF co-receptors, integrin αvβ3 and integrin α5β1. AXT107 self-assembles into a gel-like depot residing below the visual axis after intravitreal injection and releasing the active drug gradually over months.  This allows for AXT107 to potentially be dosed only once per year or even less frequently, rather than every 1 to 3 months as is required for currently approved therapies and those in clinical development for the treatment of retinal vascular diseases.


We are targeting retinal vascular diseases. Our technology utilizes a novel of mechanism of action, targeting multiple factors simultaneously that drive the pathogenesis of these diseases. In addition, we hope to achieve superior efficacy with fewer injections than currently approved therapies, while substantially reducing the treatment burden for patients.


We are developing treatments to activate anti-tumor immunity, inhibit metastasis, and enhance efficacy when used in combination with immunotherapy and chemotherapy. Early results in animal models show inhibition of tumor growth and prevention of metastasis in triple-negative breast cancer as well as survival benefits in hepatocellular carcinoma.

Innovation Leaders

AsclepiX Therapeutics was founded by Johns Hopkins University School of Medicine researchers, initially licensing their groundbreaking portfolio of vascular homeostatic peptides and technologies. AsclepiX has grown and matured over the years, and is now led by a world-class team of experienced biomedical and pharmaceutical executives who are dedicated to advancing the clinical development of these novel therapeutics, that are poised to significantly extend their utility well beyond the capabilities of today’s therapies.

We do this by translating brilliant scientific discovery into tomorrow’s transformative medicines that have the potential to bring better and dramatically lasting improvements to health to people throughout the world.

We take pride in scientific and operational excellence. Our progress is driven by the culture of curiosity, creativity, and courage built by our team members. We highly value this culture and support it every way we can.

We are dedicated every day to advancing the development of these novel therapeutics to prove their safety and efficacy in fulfilling significant unmet needs in global healthcare.